In the latest session, ImmunityBio Inc (NASDAQ: IBRX) closed at $5.11 down -15.68% from its previous closing price of $6.06. On the day, 6868176 shares were traded.
Ratios:
For a deeper understanding of ImmunityBio Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.05 and its Current Ratio is at 5.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on May 12, 2023, Downgraded its rating to Neutral and sets its target price to $4 from $10 previously.
On August 03, 2022, Jefferies started tracking the stock assigning a Buy rating and target price of $8.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 05 ’23 when BLASZYK MICHAEL D bought 71,915 shares for $2.75 per share. The transaction valued at 198,023 led to the insider holds 71,915 shares of the business.
Brennan John Owen bought 25,000 shares of IBRX for $70,700 on Jun 02 ’23. The Director now owns 25,000 shares after completing the transaction at $2.83 per share. On Jun 01 ’23, another insider, Clark Wesley, who serves as the Director of the company, bought 7,000 shares for $2.91 each. As a result, the insider paid 20,370 and bolstered with 8,000 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 5554.65.
Stock Price History:
Over the past 52 weeks, IBRX has reached a high of $6.93, while it has fallen to a 52-week low of $1.25.
Shares Statistics:
A total of 670.87M shares are outstanding, with a floating share count of 136.93M. Insiders hold about 79.68% of the company’s shares, while institutions hold 8.49% stake in the company.
Earnings Estimates
There are ImmunityBio, Inc. different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $1.50, with high estimates of $21.44 and low estimates of $40.55.
Analysts are recommending an EPS of between $Real Estate and $Financial Services for the fiscal current year, implying an average EPS of $Healthcare.
